Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.
Ylösmäki E, Ylösmäki L, Fusciello M, Martins B, Ahokas P, Cojoc H, Uoti A, Feola S, Kreutzman A, Ranki T, Karbach J, Viitala T, Priha P, Jäger E, Pesonen S, Cerullo V. Ylösmäki E, et al. Among authors: viitala t. Mol Ther Oncolytics. 2021 Feb 10;20:459-469. doi: 10.1016/j.omto.2021.02.006. eCollection 2021 Mar 26. Mol Ther Oncolytics. 2021. PMID: 33718594 Free PMC article.
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma.
Capasso C, Hirvinen M, Garofalo M, Romaniuk D, Kuryk L, Sarvela T, Vitale A, Antopolsky M, Magarkar A, Viitala T, Suutari T, Bunker A, Yliperttula M, Urtti A, Cerullo V. Capasso C, et al. Among authors: viitala t. Oncoimmunology. 2015 Oct 29;5(4):e1105429. doi: 10.1080/2162402X.2015.1105429. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141389 Free PMC article.
Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses.
Ylösmäki E, Malorzo C, Capasso C, Honkasalo O, Fusciello M, Martins B, Ylösmäki L, Louna A, Feola S, Paavilainen H, Peltonen K, Hukkanen V, Viitala T, Cerullo V. Ylösmäki E, et al. Among authors: viitala t. Mol Ther. 2018 Sep 5;26(9):2315-2325. doi: 10.1016/j.ymthe.2018.06.008. Epub 2018 Jun 19. Mol Ther. 2018. PMID: 30005865 Free PMC article.
Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery.
Saari H, Turunen T, Lõhmus A, Turunen M, Jalasvuori M, Butcher SJ, Ylä-Herttuala S, Viitala T, Cerullo V, Siljander PRM, Yliperttula M. Saari H, et al. Among authors: viitala t. J Extracell Vesicles. 2020 Apr 17;9(1):1747206. doi: 10.1080/20013078.2020.1747206. eCollection 2020. J Extracell Vesicles. 2020. PMID: 32363012 Free PMC article.
Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin.
Ylösmäki E, Fusciello M, Martins B, Feola S, Hamdan F, Chiaro J, Ylösmäki L, Vaughan MJ, Viitala T, Kulkarni PS, Cerullo V. Ylösmäki E, et al. Among authors: viitala t. J Immunother Cancer. 2021 Jul;9(7):e002707. doi: 10.1136/jitc-2021-002707. J Immunother Cancer. 2021. PMID: 34266884 Free PMC article.
Neonatal Fc receptor-targeted lignin-encapsulated porous silicon nanoparticles for enhanced cellular interactions and insulin permeation across the intestinal epithelium.
Martins JP, Figueiredo P, Wang S, Espo E, Celi E, Martins B, Kemell M, Moslova K, Mäkilä E, Salonen J, Kostiainen MA, Celia C, Cerullo V, Viitala T, Sarmento B, Hirvonen J, Santos HA. Martins JP, et al. Among authors: viitala t. Bioact Mater. 2021 Aug 10;9:299-315. doi: 10.1016/j.bioactmat.2021.08.007. eCollection 2022 Mar. Bioact Mater. 2021. PMID: 34820572 Free PMC article.
84 results